Guidelines for standard preclinical experiments in the mouse model of myasthenia gravis induced by acetylcholine receptor immunization

Erdem Tuzun, Sonia Berrih-Aknin, Talma Brenner, Linda L. Kusner, Rozen Le Panse, Huan Yang, Socrates Tzartos, Premkumar Christadoss

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Myasthenia gravis (MG) is an autoimmune disorder characterized by generalized muscle weakness due to neuromuscular junction (NMJ) dysfunction brought by acetylcholine receptor (AChR) antibodies in most cases. Although steroids and other immunosuppressants are effectively used for treatment of MG, these medications often cause severe side effects and a complete remission cannot be obtained in many cases. For pre-clinical evaluation of more effective and less toxic treatment methods for MG, the experimental autoimmune myasthenia gravis (EAMG) induced by Torpedo AChR immunization has become one of the standard animal models. Although numerous compounds have been recently proposed for MG mostly by using the active immunization EAMG model, only a few have been proven to be effective in MG patients. The variability in the experimental design, immunization methods and outcome measurements of pre-clinical EAMG studies make it difficult to interpret the published reports and assess the potential for application to MG patients. In an effort to standardize the active immunization EAMG model, we propose standard procedures for animal care conditions, sampling and randomization of mice, experimental design and outcome measures. Utilization of these standard procedures might improve the power of pre-clinical EAMG experiments and increase the chances for identifying promising novel treatment methods that can be effectively translated into clinical trials for MG.

Original languageEnglish (US)
Pages (from-to)11-17
Number of pages7
JournalExperimental Neurology
Volume270
DOIs
StatePublished - Oct 24 2014

Fingerprint

Autoimmune Experimental Myasthenia Gravis
Myasthenia Gravis
Cholinergic Receptors
Immunization
Guidelines
Vaccination
Research Design
Torpedo
Neuromuscular Junction
Poisons
Muscle Weakness
Immunosuppressive Agents
Random Allocation
Therapeutics
Animal Models
Steroids
Outcome Assessment (Health Care)
Clinical Trials
Antibodies

Keywords

  • Experimental animal model
  • Myasthenia gravis
  • Pre-clinical experiments
  • Standard operating procedures

ASJC Scopus subject areas

  • Neurology
  • Developmental Neuroscience
  • Medicine(all)

Cite this

Guidelines for standard preclinical experiments in the mouse model of myasthenia gravis induced by acetylcholine receptor immunization. / Tuzun, Erdem; Berrih-Aknin, Sonia; Brenner, Talma; Kusner, Linda L.; Le Panse, Rozen; Yang, Huan; Tzartos, Socrates; Christadoss, Premkumar.

In: Experimental Neurology, Vol. 270, 24.10.2014, p. 11-17.

Research output: Contribution to journalArticle

Tuzun, Erdem ; Berrih-Aknin, Sonia ; Brenner, Talma ; Kusner, Linda L. ; Le Panse, Rozen ; Yang, Huan ; Tzartos, Socrates ; Christadoss, Premkumar. / Guidelines for standard preclinical experiments in the mouse model of myasthenia gravis induced by acetylcholine receptor immunization. In: Experimental Neurology. 2014 ; Vol. 270. pp. 11-17.
@article{33d212dde773419ab50c40836c771d0c,
title = "Guidelines for standard preclinical experiments in the mouse model of myasthenia gravis induced by acetylcholine receptor immunization",
abstract = "Myasthenia gravis (MG) is an autoimmune disorder characterized by generalized muscle weakness due to neuromuscular junction (NMJ) dysfunction brought by acetylcholine receptor (AChR) antibodies in most cases. Although steroids and other immunosuppressants are effectively used for treatment of MG, these medications often cause severe side effects and a complete remission cannot be obtained in many cases. For pre-clinical evaluation of more effective and less toxic treatment methods for MG, the experimental autoimmune myasthenia gravis (EAMG) induced by Torpedo AChR immunization has become one of the standard animal models. Although numerous compounds have been recently proposed for MG mostly by using the active immunization EAMG model, only a few have been proven to be effective in MG patients. The variability in the experimental design, immunization methods and outcome measurements of pre-clinical EAMG studies make it difficult to interpret the published reports and assess the potential for application to MG patients. In an effort to standardize the active immunization EAMG model, we propose standard procedures for animal care conditions, sampling and randomization of mice, experimental design and outcome measures. Utilization of these standard procedures might improve the power of pre-clinical EAMG experiments and increase the chances for identifying promising novel treatment methods that can be effectively translated into clinical trials for MG.",
keywords = "Experimental animal model, Myasthenia gravis, Pre-clinical experiments, Standard operating procedures",
author = "Erdem Tuzun and Sonia Berrih-Aknin and Talma Brenner and Kusner, {Linda L.} and {Le Panse}, Rozen and Huan Yang and Socrates Tzartos and Premkumar Christadoss",
year = "2014",
month = "10",
day = "24",
doi = "10.1016/j.expneurol.2015.02.009",
language = "English (US)",
volume = "270",
pages = "11--17",
journal = "Experimental Neurology",
issn = "0014-4886",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Guidelines for standard preclinical experiments in the mouse model of myasthenia gravis induced by acetylcholine receptor immunization

AU - Tuzun, Erdem

AU - Berrih-Aknin, Sonia

AU - Brenner, Talma

AU - Kusner, Linda L.

AU - Le Panse, Rozen

AU - Yang, Huan

AU - Tzartos, Socrates

AU - Christadoss, Premkumar

PY - 2014/10/24

Y1 - 2014/10/24

N2 - Myasthenia gravis (MG) is an autoimmune disorder characterized by generalized muscle weakness due to neuromuscular junction (NMJ) dysfunction brought by acetylcholine receptor (AChR) antibodies in most cases. Although steroids and other immunosuppressants are effectively used for treatment of MG, these medications often cause severe side effects and a complete remission cannot be obtained in many cases. For pre-clinical evaluation of more effective and less toxic treatment methods for MG, the experimental autoimmune myasthenia gravis (EAMG) induced by Torpedo AChR immunization has become one of the standard animal models. Although numerous compounds have been recently proposed for MG mostly by using the active immunization EAMG model, only a few have been proven to be effective in MG patients. The variability in the experimental design, immunization methods and outcome measurements of pre-clinical EAMG studies make it difficult to interpret the published reports and assess the potential for application to MG patients. In an effort to standardize the active immunization EAMG model, we propose standard procedures for animal care conditions, sampling and randomization of mice, experimental design and outcome measures. Utilization of these standard procedures might improve the power of pre-clinical EAMG experiments and increase the chances for identifying promising novel treatment methods that can be effectively translated into clinical trials for MG.

AB - Myasthenia gravis (MG) is an autoimmune disorder characterized by generalized muscle weakness due to neuromuscular junction (NMJ) dysfunction brought by acetylcholine receptor (AChR) antibodies in most cases. Although steroids and other immunosuppressants are effectively used for treatment of MG, these medications often cause severe side effects and a complete remission cannot be obtained in many cases. For pre-clinical evaluation of more effective and less toxic treatment methods for MG, the experimental autoimmune myasthenia gravis (EAMG) induced by Torpedo AChR immunization has become one of the standard animal models. Although numerous compounds have been recently proposed for MG mostly by using the active immunization EAMG model, only a few have been proven to be effective in MG patients. The variability in the experimental design, immunization methods and outcome measurements of pre-clinical EAMG studies make it difficult to interpret the published reports and assess the potential for application to MG patients. In an effort to standardize the active immunization EAMG model, we propose standard procedures for animal care conditions, sampling and randomization of mice, experimental design and outcome measures. Utilization of these standard procedures might improve the power of pre-clinical EAMG experiments and increase the chances for identifying promising novel treatment methods that can be effectively translated into clinical trials for MG.

KW - Experimental animal model

KW - Myasthenia gravis

KW - Pre-clinical experiments

KW - Standard operating procedures

UR - http://www.scopus.com/inward/record.url?scp=84939426065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939426065&partnerID=8YFLogxK

U2 - 10.1016/j.expneurol.2015.02.009

DO - 10.1016/j.expneurol.2015.02.009

M3 - Article

C2 - 25697844

AN - SCOPUS:84939426065

VL - 270

SP - 11

EP - 17

JO - Experimental Neurology

JF - Experimental Neurology

SN - 0014-4886

ER -